Truist Financial Corp Sells 678 Shares of BioNTech SE (NASDAQ:BNTX)

Truist Financial Corp lessened its position in BioNTech SE (NASDAQ:BNTX) by 4.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,784 shares of the company’s stock after selling 678 shares during the period. Truist Financial Corp’s holdings in BioNTech were worth $1,268,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in BNTX. Candriam S.C.A. boosted its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after purchasing an additional 341,311 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of BioNTech by 610.5% in the 1st quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock valued at $6,471,000 after purchasing an additional 60,270 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of BioNTech by 51.3% in the 1st quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock valued at $10,275,000 after purchasing an additional 37,792 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of BioNTech in the 2nd quarter valued at $2,892,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX stock opened at $120.52 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The stock has a market cap of $28.66 billion, a PE ratio of -53.33 and a beta of 0.24. The stock has a 50-day moving average of $100.90 and a 200-day moving average of $93.36. BioNTech SE has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same period last year, the company earned ($0.86) earnings per share. The business’s revenue was down 23.3% compared to the same quarter last year. As a group, sell-side analysts expect that BioNTech SE will post -3.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BNTX. TD Cowen reduced their target price on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. HC Wainwright upped their price target on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and upped their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $93.00 to $145.00 in a research report on Tuesday, September 24th. Finally, HSBC upped their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus target price of $131.92.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.